KADCYLA 100MG INJECTION

KADCYLA 100MG INJECTION can cause peripheral neuropathy, a type of nerve damage that can cause tingling, numbness, or weakness in the hands and feet. If you experience these symptoms during treatment, discuss them with your healthcare provider.

KADCYLA 100MG INJECTION can cause temporary infertility in some patients, particularly women. If fertility preservation is a concern for you, discuss this with your healthcare provider before starting treatment.

KADCYLA 100MG INJECTION is a type of chemotherapy, but it is designed to target HER2-positive cancer cells specifically, which may result in fewer side effects than traditional chemotherapy. Additionally, it is given as a single medication, rather than as a combination of drugs.

KADCYLA 100MG INJECTION may be used in combination with other cancer treatments, such as chemotherapy or targeted therapies. Your healthcare provider can help determine the best treatment plan for you based on your individual needs and medical history.

The use of KADCYLA 100MG INJECTION in patients with active tuberculosis (TB) is not recommended due to the risk of worsening the TB infection. This medication can suppress the immune system, making it harder for the body to fight off infections such as TB. Before starting treatment, your healthcare provider will perform a thorough evaluation of your medical history, including screening for TB.

KADCYLA 100MG INJECTION can cause heart problems, particularly in patients with preexisting heart conditions or risk factors. Your healthcare provider will monitor your heart function closely during treatment.

Yes, KADCYLA 100MG INJECTION may interact with certain other medications. It is crucial to inform your healthcare provider about all the medicines, supplements, and herbal products you are currently taking to avoid potential interactions.

If you are receiving KADCYLA 100MG INJECTION, it's important to be proactive in managing your treatment and monitoring your symptoms. Keep communication with your healthcare provider and report any concerns or side effects as soon as possible. Avoid getting pregnant and breastfeeding during treatment. Use effective birth control during the treatment and at least 7 weeks after the last dose. Immediately contact your healthcare provider in case of any worsening of symptoms or infusion reactions. Take steps to care for yourself physically and emotionally during treatment, and seek support from loved ones and professionals as needed. Maintain a healthy and balanced diet during treatment to support your overall health and well-being. Being informed and engaged in your treatment can help ensure the best possible outcomes and manage potential risks or complications.

ADO-TRASTUZUMAB EMTANSINE is the active ingredient or molecule used to make KADCYLA 100MG INJECTION. It is an antibody-drug conjugate designed to specifically target cancer cells.

KADCYLA 100MG INJECTION is primarily used to treat certain types of breast cancer that are HER2-positive. Your doctor will determine if this treatment is suitable for your specific condition.

KADCYLA 100MG INJECTION works by targeting and delivering a potent chemotherapy drug directly to HER2-positive cancer cells, minimizing damage to healthy cells.